• LAST PRICE
    0.0040
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    --- / 0.0040
  • Day Range
    ---
  • 52 Week Range
    Low 0.0016
    High 0.0390
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRASP
Actavia Life Sciences Inc
3.1M
-7.5x
---
United StatesREVB
Revelation Biosciences Inc
3.1M
0.0x
---
United StatesTHAR
Tharimmune Inc
3.1M
-0.1x
---
United StatesSCNI
Scinai Immunotherapeutics Ltd
3.0M
-0.4x
---
United StatesTNFA
TNF Pharmaceuticals Inc
3.2M
-0.2x
---
United StatesGRI
GRI Bio Inc
3.2M
0.0x
---
As of 2024-11-04

Company Information

Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.

Contact Information

Headquarters
5 Penn Plaza, 19th Floor, #1954NEW YORK, NY, United States 10001
Phone
646-396-4087
Fax
---

Executives

Independent Chairman of the Board
Willy Simon
Finance Director
Keeren Shah
Independent Director
John Brancaccio
Independent Director
Gary Jacob

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.1M
Revenue (TTM)
$0.00
Shares Outstanding
771.8M
Actavia Life Sciences Inc does not pay a dividend.
Beta
---
EPS
$0.00
Book Value
$0.00
P/E Ratio
-7.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.